Evommune (EVMN) Research & Development (2024 - 2026)

Evommune (EVMN) has reported Research & Development for 3 consecutive years, with $6.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 64.46% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $60.3 million (changed N/A YoY), while the FY2025 annual figure was $74.0 million, up 15.25% from the prior year.
• Research & Development declined to $6.7 million in Q1 2026 per EVMN's latest filing, from $29.9 million in the prior quarter.
• Across five years, Research & Development topped out at $57.5 million in Q4 2024 and bottomed at $2.8 million in Q3 2024.
• Historically, Research & Development has averaged $20.1 million across 3 years, with a median of $13.2 million in 2025.
• On a YoY basis, Research & Development climbed as much as 600.39% in 2025 and fell as far as 47.96% in 2025.
• Evommune's Research & Development stood at $57.5 million in 2024, then sank by 47.96% to $29.9 million in 2025, then tumbled by 77.72% to $6.7 million in 2026.
• Business Quant data shows EVMN's Research & Development at $6.7 million in Q1 2026, $29.9 million in Q4 2025, and $19.6 million in Q3 2025.